论文部分内容阅读
肺结核是一类严重危害人类生命健康的传染性疾病,尤其随着耐多药结核分枝杆菌(MDR-TB)、广谱耐药结核杆菌(XDR-TB)以及与HIV等混合感染的出现,迫切需要研发新的药物来解决这一困难。即使是对药物敏感性肺结核(DS-TB),也需要缩短治疗时间,以防止持久用药产生耐药性。在过去的十年中,结核药物研发已取得重大进展,但是仍存在严峻的挑战。本文通过简单介绍目前肺结核流行形势,进而阐述肺结核治疗所面临的挑战以及理想药物应具备的特点,并对肺结核新药研发的首选对策与应用实例加以综述。
Tuberculosis is a kind of infectious disease that seriously endangers the health of human beings. Especially with the emergence of mixed infections such as multidrug-resistant Mycobacterium tuberculosis (MDR-TB), broad-spectrum drug-resistant Mycobacterium tuberculosis (XDR-TB) and HIV, There is an urgent need to develop new drugs to solve this problem. Even with drug-susceptible pulmonary tuberculosis (DS-TB), there is a need to shorten the duration of treatment to prevent long-term drug-resistance. In the past decade, significant progress has been made in the development of tuberculosis drugs, but there are still serious challenges. This article briefly introduces the current situation of tuberculosis epidemic, and then elaborates the challenges of tuberculosis treatment as well as the characteristics that ideal drugs should possess. And reviews the preferred countermeasures and application examples of new tuberculosis drug development.